Unlock instant, AI-driven research and patent intelligence for your innovation.

A miRNA marker for risk assessment of lung cancer

A technology of markers and risk scoring, applied in the field of biomedicine, can solve problems such as insufficient sensitivity and accuracy of lung cancer risk, no reference standard for lung cancer risk determination, and little knowledge of effective molecules

Active Publication Date: 2021-04-13
XUZHOU MEDICAL UNIV
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it is difficult to accurately diagnose early lung cancer by using imaging methods alone, and there is still a lack of effective biomarkers combined with imaging techniques (LDCT) to improve the specificity of early lung cancer diagnosis
[0004] Potent molecules for predicting lung cancer risk are poorly understood
In addition, many published studies only focus on a single indicator to diagnose lung cancer risk
However, single molecules as biomarkers are not sensitive and accurate enough to diagnose lung cancer risk
[0005] At present, multiple molecules as biomarkers have no reference standards for the risk assessment of lung cancer, and there are no specific indicators, which are far from meeting the needs of risk assessment for lung cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A miRNA marker for risk assessment of lung cancer
  • A miRNA marker for risk assessment of lung cancer
  • A miRNA marker for risk assessment of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1 Screening miRNAs associated with lung cancer

[0082] 1. Sample

[0083] The samples in GSE106817, GSE112264, GSE113486, GSE122497, GSE124158, GSE137140, and GSE139031 were selected from the GEO database as the research objects. A total of 10475 normal individuals and 1801 lung cancer patients had serum circulating miRNA expression profile data.

[0084] Randomly select 300 cases of data from 10475 normal people as the test set, and the remaining data as the training set; randomly select 300 cases of data from 1801 lung cancer patients as the test set, and the remaining data as the training set;

[0085] 2. Data normalization processing

[0086] Normalize the test set data and training set data; a) normalize the data to the (0,1) interval or (1,1) interval; b) change the dimensioned expression into a dimensionless expression;

[0087] 3) Screen differentially expressed molecules

[0088] The edgeR package was used to screen out differentially expressed miRN...

Embodiment 2

[0091] Example 2 Construction of risk scoring model

[0092] A risk scoring model was constructed using a 1D convolutional neural network model.

[0093] The input tensor dimension of the 1-dimensional convolutional neural network model is (length, 1), where length represents the number of selected feature miRNAs. The main body of the model includes an initial convolutional layer (init_conv), eight residual convolutional modules (res_block), a global pooling layer (GlobalAveragePooling), a fully connected layer (Dense) and an activation output layer (Sigmoid). Among them, conv is a one-dimensional convolution operation, k represents the size of the convolution kernel, and filters represent the number of convolution kernels. BatchNorm is a batch normalization layer, which normalizes the output tensor of the previous layer to a standard normal distribution with a mean of 0 and a variance of 1, so as to alleviate the gradient dispersion and gradient explosion in network training...

Embodiment 3

[0095] Example 3 Diagnostic efficacy testing of risk scoring model

[0096] In the training set, the results of using the risk scoring model of the present invention to diagnose the risk of lung cancer in subjects showed that a single miRNA or a combination of several miRNAs can be used as an independent prognostic factor for the diagnosis of lung cancer risk, and 3 or 4 miRNAs combined The area under the curve (AUC) formed is the highest, as shown in Table 1 and Figure 1-15 shown.

[0097] Table 1 Area under the curve formed by different miRNA markers

[0098] miRNA AUC hsa-miR-125a-3p 0.77 hsa-miR-3615 0.80 hsa-miR-4730 0.54 hsa-miR-575 0.90 hsa-miR-125a-3p+hsa-miR-3615 0.96 hsa-miR-125a-3p+hsa-miR-4730 0.98 hsa-miR-125a-3p+hsa-miR-575 0.97 hsa-miR-3615+hsa-miR-4730 0.98 hsa-miR-3615+hsa-miR-575 0.97 hsa-miR-4730+hsa-miR-575 0.98 hsa-miR-125a-3p+hsa-miR-3615+hsa-miR-4730 0.99 hsa-miR-125a-3p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a miRNA marker for lung cancer risk assessment, the miRNA marker includes at least hsa-miR-4730, hsa-miR-125a, hsa-miR-3615, hsa-miR-575 One. The AUC values ​​of the miRNA markers of the present invention for diagnosing the risk of lung cancer are all above 0.90, and the research results are of great significance for the assessment of the risk of lung cancer.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a miRNA marker used for risk assessment of lung cancer. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality worldwide. The early stage of lung cancer is hidden and usually asymptomatic, but most patients are already in the middle and late stages when they are first diagnosed, and have lost the opportunity for surgical resection. The five-year survival rate of advanced lung cancer patients is less than 5%, while the five-year survival rate of early lung cancer patients can reach more than 90%. Therefore, early diagnosis is an important opportunity for lung cancer patients to obtain a good prognosis. [0003] At present, the early diagnosis methods of lung cancer include chest imaging, bronchoscopy technology and sputum exfoliation cytology detection, etc., but the detection effect of these methods is not ideal. The sensitivity of sputu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/113G16B5/00G06N3/04G06N3/08
CPCC12Q1/6886G16B5/00G06N3/08C12Q2600/158C12Q2600/178G06N3/045
Inventor 陈艺尹吴佳伟朱鹏霖林媛媛范宏伟赵丹丹李淇张素芳常乐耿晟
Owner XUZHOU MEDICAL UNIV